Jessica Fye
Stock Analyst at JP Morgan
(4.58)
# 217
Out of 5,076 analysts
219
Total ratings
62.32%
Success rate
17.15%
Average return
Main Sectors:
Stocks Rated by Jessica Fye
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DNLI Denali Therapeutics | Maintains: Overweight | $24 → $26 | $18.16 | +43.17% | 6 | Nov 4, 2025 | |
| STOK Stoke Therapeutics | Maintains: Neutral | $15 → $25 | $30.09 | -16.92% | 5 | Nov 3, 2025 | |
| NVCR NovoCure | Maintains: Neutral | $25 → $23 | $11.68 | +96.92% | 5 | Oct 27, 2025 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Overweight | $204 → $199 | $172.12 | +15.62% | 5 | Oct 27, 2025 | |
| HALO Halozyme Therapeutics | Maintains: Neutral | $63 → $65 | $68.10 | -4.55% | 15 | Oct 27, 2025 | |
| MRNA Moderna | Maintains: Underweight | $26 → $25 | $24.16 | +3.48% | 14 | Oct 23, 2025 | |
| BNTX BioNTech SE | Maintains: Neutral | $121 → $120 | $97.39 | +23.22% | 14 | Oct 23, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Overweight | $475 → $473 | $454.56 | +4.06% | 9 | Oct 13, 2025 | |
| LEGN Legend Biotech | Maintains: Overweight | $78 → $76 | $26.84 | +183.16% | 4 | Oct 9, 2025 | |
| INCY Incyte | Maintains: Neutral | $73 → $89 | $102.04 | -12.78% | 9 | Oct 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $116 → $119 | $55.03 | +116.25% | 5 | Oct 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $260 → $264 | $210.88 | +25.19% | 16 | Oct 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $517 → $530 | $425.60 | +24.53% | 10 | Oct 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $345 → $385 | $335.88 | +14.62% | 4 | Oct 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $49 → $80 | $81.99 | -2.43% | 7 | Oct 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $53 → $52 | $45.32 | +14.74% | 6 | Sep 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $53 → $77 | $70.01 | +9.98% | 4 | Sep 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $34 → $35 | $28.90 | +21.11% | 7 | Sep 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $111 → $135 | $211.41 | -36.14% | 9 | Aug 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $350 → $330 | $479.95 | -31.24% | 17 | Jul 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $10 → $13 | $7.13 | +82.33% | 6 | May 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $54 → $50 | $37.59 | +33.01% | 5 | Apr 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $32.98 | -9.04% | 1 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Underweight | n/a | $61.11 | - | 7 | Nov 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Underweight | n/a | $10.79 | - | 2 | Nov 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | n/a | $3.72 | - | 9 | Nov 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Underweight | n/a | $15.59 | - | 6 | Nov 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $1.11 | - | 2 | Aug 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $7 | $1.36 | +414.71% | 2 | Jan 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $27.45 | - | 4 | Mar 11, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $6.69 | - | 3 | Feb 28, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $14.14 | - | 1 | Feb 8, 2018 |
Denali Therapeutics
Nov 4, 2025
Maintains: Overweight
Price Target: $24 → $26
Current: $18.16
Upside: +43.17%
Stoke Therapeutics
Nov 3, 2025
Maintains: Neutral
Price Target: $15 → $25
Current: $30.09
Upside: -16.92%
NovoCure
Oct 27, 2025
Maintains: Neutral
Price Target: $25 → $23
Current: $11.68
Upside: +96.92%
Jazz Pharmaceuticals
Oct 27, 2025
Maintains: Overweight
Price Target: $204 → $199
Current: $172.12
Upside: +15.62%
Halozyme Therapeutics
Oct 27, 2025
Maintains: Neutral
Price Target: $63 → $65
Current: $68.10
Upside: -4.55%
Moderna
Oct 23, 2025
Maintains: Underweight
Price Target: $26 → $25
Current: $24.16
Upside: +3.48%
BioNTech SE
Oct 23, 2025
Maintains: Neutral
Price Target: $121 → $120
Current: $97.39
Upside: +23.22%
Alnylam Pharmaceuticals
Oct 13, 2025
Maintains: Overweight
Price Target: $475 → $473
Current: $454.56
Upside: +4.06%
Legend Biotech
Oct 9, 2025
Maintains: Overweight
Price Target: $78 → $76
Current: $26.84
Upside: +183.16%
Incyte
Oct 9, 2025
Maintains: Neutral
Price Target: $73 → $89
Current: $102.04
Upside: -12.78%
Oct 9, 2025
Maintains: Overweight
Price Target: $116 → $119
Current: $55.03
Upside: +116.25%
Oct 9, 2025
Maintains: Overweight
Price Target: $260 → $264
Current: $210.88
Upside: +25.19%
Oct 8, 2025
Maintains: Overweight
Price Target: $517 → $530
Current: $425.60
Upside: +24.53%
Oct 8, 2025
Maintains: Overweight
Price Target: $345 → $385
Current: $335.88
Upside: +14.62%
Oct 8, 2025
Upgrades: Overweight
Price Target: $49 → $80
Current: $81.99
Upside: -2.43%
Sep 24, 2025
Maintains: Overweight
Price Target: $53 → $52
Current: $45.32
Upside: +14.74%
Sep 12, 2025
Maintains: Overweight
Price Target: $53 → $77
Current: $70.01
Upside: +9.98%
Sep 9, 2025
Maintains: Neutral
Price Target: $34 → $35
Current: $28.90
Upside: +21.11%
Aug 20, 2025
Maintains: Overweight
Price Target: $111 → $135
Current: $211.41
Upside: -36.14%
Jul 8, 2025
Maintains: Overweight
Price Target: $350 → $330
Current: $479.95
Upside: -31.24%
May 6, 2025
Maintains: Overweight
Price Target: $10 → $13
Current: $7.13
Upside: +82.33%
Apr 14, 2025
Maintains: Overweight
Price Target: $54 → $50
Current: $37.59
Upside: +33.01%
Oct 8, 2024
Initiates: Overweight
Price Target: $30
Current: $32.98
Upside: -9.04%
Nov 20, 2023
Reinstates: Underweight
Price Target: n/a
Current: $61.11
Upside: -
Nov 20, 2023
Reinstates: Underweight
Price Target: n/a
Current: $10.79
Upside: -
Nov 20, 2023
Reinstates: Neutral
Price Target: n/a
Current: $3.72
Upside: -
Nov 20, 2023
Reinstates: Underweight
Price Target: n/a
Current: $15.59
Upside: -
Aug 20, 2021
Downgrades: Underweight
Price Target: n/a
Current: $1.11
Upside: -
Jan 29, 2021
Upgrades: Neutral
Price Target: $7
Current: $1.36
Upside: +414.71%
Mar 11, 2019
Downgrades: Underweight
Price Target: n/a
Current: $27.45
Upside: -
Feb 28, 2019
Downgrades: Underweight
Price Target: n/a
Current: $6.69
Upside: -
Feb 8, 2018
Downgrades: Neutral
Price Target: n/a
Current: $14.14
Upside: -